Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mechanism found that ’protects’ aggressive melanoma from angiogenesis inhibitors

08.10.2004


Northwestern University researchers have discovered a mechanism that may help to explain how angiogenesis inhibitors work on normal, blood vessel-forming endothelial cells, but not on insidious, aggressive melanoma cells that masquerade as endothelial-like cells by forming their own vascular networks, called "vasculogenic mimicry."



Mary J. C. Hendrix, professor of pediatrics at Northwestern University Feinberg School of Medicine and president and scientific director of the Children’s Memorial Research Center, led the study, results of which were published in the Oct. 6 issue of the Journal of the National Cancer Institute. Hendrix and her laboratory team are also members of The Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Hendrix and colleagues found that endostatin and two other angiogenesis inhibitors, which prevent new blood vessel growth that supports the spread of cancerous tumors, were effective in blocking endothelial cell formation of vascular networks, but were unable to prevent vascular networks formed by melanoma cells.


Further experiments showed that endothelial cells have more endostatin receptors than melanoma cells, suggesting a mechanistic basis for the differential response of the two cell types to angiogenesis inhibitors. Findings from the study may contribute to the development of new cancer therapies that target both angiogenesis and tumor cell vasculogenic mimicry. Moreover, because vasculogenic mimicry has been reported in several other tumor types, including breast, prostatic, ovarian and lung cancer, these findings may offer new insights for designing rational antivascular therapies in other forms of cancer, Hendrix said.

In the past decade, many new angiogenesis inhibitors have been identified, and several have been shown effective against tumor growth in laboratory experiments. However, results of early clinical trials with these inhibitors have not yet paralleled the success achieved in animal models. In their recent experiments, Hendrix and co-researchers examined effects of three angiogenesis inhibitors with different specificities (anginex, TNP-470, and endostatin) on vasculogenic mimicry in human melanoma cells and compared the results with effects on human endothelial cells.

Endothelial cell growth and migration were markedly inhibited by anginex, TNP-470 and endostatin, while the melanoma cells were relatively unaffected. The scientists subsequently investigated whether endothelial cells and melanoma cells expressed different levels of two newly discovered receptors (alpha 5 beta 1 integrin and heparin sulfate proteoglycan 2) for the angiogenesis inhibitor endostatin. Results showed that endothelial cells have significantly higher levels of these receptors.

"The differential response of endothelial cells and melanoma cells to angiogenesis inhibitors in our study may provide additional clues about the mechanistic interactions between endothelia and proliferating tumors and suggest additional targets for antivascular and antiangiogenic drug therapy," Hendrix said.

Hendrix’s co-researchers on this study were: Richard E. B. Seftor; Elizabeth A. Seftor; Angela R. Hess; Lynn M. Gruman; and Dawn A. Kirschmann, Children’s Memorial Research Center, Northwestern University Feinberg School of Medicine and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Daisy W.J. van der Schaft, and Arjan W. Griffioen are affiliated with the Research Institute for Growth and Development, Maastricht, The Netherlands. Yumi Yokoyama is with the University of Minnesota, Minneapolis.

Elizabeth Crown | EurekAlert!
Further information:
http://www.northwestern.edu

More articles from Life Sciences:

nachricht Molecular Force Sensors
20.09.2017 | Max-Planck-Institut für Biochemie

nachricht Foster tadpoles trigger parental instinct in poison frogs
20.09.2017 | Veterinärmedizinische Universität Wien

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Molecular Force Sensors

20.09.2017 | Life Sciences

Producing electricity during flight

20.09.2017 | Power and Electrical Engineering

Tiny lasers from a gallery of whispers

20.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>